BridgeMD
New treatment option for Malignant Brain Neoplasm
Official title Feasibility of FMISO in Brain Tumors
ClinicalTrials.gov ID: NCT03649880
What this study is testing
What is ¹⁸F-Fluoromisonidazole?
¹⁸F-Fluoromisonidazole is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for malignant brain neoplasm.
Also referred to as ¹⁸F-MISO, ¹⁸F-Misonidazole.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 5 years
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult patients (greater than 18 years of age) with a known or suspected intracranial tumor.
- Able to provide informed written consent and/or acceptable surrogate capable of providing consent on the patient's behalf.
- Legally authorized representative (LAR)-signed informed consent and assent obtained for those people identified as decisionally impaired
- Intracranial lesion known or suspected to be neoplastic greater than 10 mL as assessed by T2/fluid attenuated inversion recovery (FLAIR) MR imaging.
- Karnofsky performance score \> 60 or Eastern Cooperative Oncology Group (ECOG) \< 3 as assessed by referring clinician.
You likely can't join if
- Pregnant or breast feeding.
- Contraindication to PET, MRI, FMISO, or intravenous gadolinium based contrast agents.
- Claustrophobia.
- Weight greater than modality maximum capacity.
- Presence of metallic foreign body or implanted medical devices in body not documented as MRI safe according to the Oregon Health \& Science...
- Sickle cell disease.
See the full eligibility criteria
- Adult patients (greater than 18 years of age) with a known or suspected intracranial tumor.
- Able to provide informed written consent and/or acceptable surrogate capable of providing consent on the patient's behalf.
- Legally authorized representative (LAR)-signed informed consent and assent obtained for those people identified as decisionally impaired
- Intracranial lesion known or suspected to be neoplastic greater than 10 mL as assessed by T2/fluid attenuated inversion recovery (FLAIR) MR imaging.
- Karnofsky performance score \> 60 or Eastern Cooperative Oncology Group (ECOG) \< 3 as assessed by referring clinician.
- Planning to undergo or previously received therapeutic intervention for the intracranial tumor.
- Pregnant or breast feeding.
- Contraindication to PET, MRI, FMISO, or intravenous gadolinium based contrast agents.
- Claustrophobia.
- Weight greater than modality maximum capacity.
- Presence of metallic foreign body or implanted medical devices in body not documented as MRI safe according to the Oregon Health \& Science University (OHSU) Department of Radiology guidelines (including but not limited...
- Sickle cell disease.
- Reduced renal function, as determined by glomerular filtration rate (GFR) \< 45 mL/min/1.73 m\^2 based on a serum creatinine level obtained per OHSU Department of Radiology and Advanced Imaging Research Center (AIRC)...
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to FMISO. An allergic reaction to nitroimidazoles is highly unlikely.
- Unsure of pregnancy status as assessed by Department of Radiology and AIRC guidelines.
- people for whom supplemental oxygen could be harmful such as people with potential for hypoventilation (end-stage COPD, OSA on CPAP/Bi-PAP, etc).
- people with a relative contraindication to supplemental oxygen administration will not be provided oxygen but may still participate in the study.
- Presence of any other co-existing condition that, in the judgment of the principal investigator, might increase the risk to the subject (i.e., plans for hospice or end of life care).
- Poor peripheral intravenous access evaluated by patient history.
- Presence of other serious systemic illnesses, including: uncontrolled infection, other uncontrolled malignancy, uncontrolled diabetes type II, or psychiatric/social situations which might impact the endpoint of the...
The study team makes the final eligibility decision.
Where it's taking place
- Portland, Oregon, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 5 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Portland, Oregon, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.